{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:11:51Z","timestamp":1783977111171,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07057-2","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T02:16:46Z","timestamp":1778293006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Romiplostim in the management of severe aplastic anemia: a comprehensive clinical review"],"prefix":"10.1007","volume":"105","author":[{"given":"Mostafa F.","family":"Mohammed Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Kotb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Alfadil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazza","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alahmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"7057_CR1","doi-asserted-by":"publisher","first-page":"1378432","DOI":"10.3389\/fimmu.2024.1378432","volume":"15","author":"A Piekarska","year":"2024","unstructured":"Piekarska A et al (2024) The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults. Front Immunol 15:1378432","journal-title":"Front Immunol"},{"issue":"4","key":"7057_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1053\/j.seminhematol.2019.09.001","volume":"56","author":"J Bussel","year":"2019","unstructured":"Bussel J et al (2019) Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Semin Hematol 56(4):262\u2013278","journal-title":"Semin Hematol"},{"key":"7057_CR3","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/DDDT.S299591","volume":"15","author":"JB Bussel","year":"2021","unstructured":"Bussel JB et al (2021) A Review of Romiplostim Mechanism of Action and Clinical Applicability. Drug Des Devel Ther 15:2243\u20132268","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"7057_CR4","first-page":"e37682","volume":"15","author":"G Dhingra","year":"2023","unstructured":"Dhingra G, Rajoreya A (2023) A Single-Centre Experience of First-Line Romiplostim and Immunosuppressive Therapy in Patients With Aplastic Anemia. Cureus 15(4):e37682","journal-title":"Cureus"},{"issue":"22","key":"7057_CR5","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1182\/bloodadvances.2024014855","volume":"9","author":"JW Lee","year":"2025","unstructured":"Lee JW et al (2025) Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia. Blood Adv 9(22):5732\u20135735","journal-title":"Blood Adv"},{"issue":"2","key":"7057_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/bjh.20206","volume":"207","author":"JW Lee","year":"2025","unstructured":"Lee JW et al (2025) Romiplostim with ciclosporin A in patients with aplastic anaemia na\u00efve to immunosuppressive therapy: A phase 2\/3 study. Br J Haematol 207(2):582\u2013590","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"7057_CR7","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1182\/blood-2024-193925","volume":"144","author":"K Hosokawa","year":"2024","unstructured":"Hosokawa K et al (2024) Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2\/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis. Blood 144(Supplement 1):1310\u20131310","journal-title":"Blood"},{"issue":"3","key":"7057_CR8","first-page":"1061","volume":"111","author":"M Bordbar","year":"2026","unstructured":"Bordbar M et al (2026) Safety and efficacy of romiplostim in children with acquired aplastic anemia who are na\u00efve to immunosuppressive therapy. Haematologica 111(3):1061\u20131064","journal-title":"Haematologica"},{"issue":"5","key":"7057_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/MPH.0000000000002891","volume":"46","author":"A Sharathkumar","year":"2024","unstructured":"Sharathkumar A et al (2024) Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome. J Pediatr Hematol Oncol 46(5):252\u2013261","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"7057_CR10","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1097\/MPH.0000000000001810","volume":"43","author":"A Al-Huniti","year":"2021","unstructured":"Al-Huniti A et al (2021) Up-front Treatment With Romiplostim in Children With Acquired Bone Marrow Failure: A Single Institutional Pediatric Case Series. J Pediatr Hematol Oncol 43(3):e431\u2013e435","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"7057_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s12185-021-03165-z","volume":"114","author":"H Yoshinari","year":"2021","unstructured":"Yoshinari H et al (2021) Rapid blood cell recovery with immunosuppressive therapy combined with romiplostim in a patient with very severe hepatitis-associated aplastic anemia who underwent liver transplantation. Int J Hematol 114(4):524\u2013527","journal-title":"Int J Hematol"},{"issue":"1","key":"7057_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bjh.17190","volume":"192","author":"JH Jang","year":"2021","unstructured":"Jang JH et al (2021) Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II\/III, multicentre, open-label study. Br J Haematol 192(1):190\u2013199","journal-title":"Br J Haematol"},{"issue":"11","key":"7057_CR13","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.1016\/S2352-3026(19)30153-X","volume":"6","author":"JW Lee","year":"2019","unstructured":"Lee JW et al (2019) Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol 6(11):e562\u2013e572","journal-title":"Lancet Haematol"},{"issue":"6","key":"7057_CR14","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1182\/bloodadvances.2023010959","volume":"8","author":"K Mitani","year":"2024","unstructured":"Mitani K et al (2024) Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2\/3 study. Blood Adv 8(6):1415\u20131419","journal-title":"Blood Adv"},{"issue":"8","key":"7057_CR15","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1007\/s00277-025-06337-7","volume":"104","author":"JH Jang","year":"2025","unstructured":"Jang JH et al (2025) Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials. Ann Hematol 104(8):4003\u20134011","journal-title":"Ann Hematol"},{"issue":"1","key":"7057_CR16","first-page":"e78228","volume":"17","author":"V Ramanan","year":"2025","unstructured":"Ramanan V, Kelkar K (2025) Romiplostim in Aplastic Anemia: A Single-Center Retrospective Study. Cureus 17(1):e78228","journal-title":"Cureus"},{"issue":"6","key":"7057_CR17","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s12185-020-02971-1","volume":"112","author":"M Ise","year":"2020","unstructured":"Ise M et al (2020) Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study. Int J Hematol 112(6):787\u2013794","journal-title":"Int J Hematol"},{"issue":"2","key":"7057_CR18","first-page":"92","volume":"66","author":"S Sato","year":"2025","unstructured":"Sato S et al (2025) [Efficacy and safety of romiplostim in aplastic anemia refractory or intolerant to immunosuppressive therapy with eltrombopag]. Rinsho Ketsueki 66(2):92\u201399","journal-title":"Rinsho Ketsueki"},{"issue":"Supplement 1","key":"7057_CR19","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1182\/blood-2024-200421","volume":"144","author":"X Lin","year":"2024","unstructured":"Lin X et al (2024) Effective Treatment of Refractory Aplastic Anemia with Romiplostim after Failure of Multiple Thrombopoietin Receptor Agonists: A Single-Center Retrospective Study. Blood 144(Supplement 1):4077\u20134077","journal-title":"Blood"},{"issue":"3","key":"7057_CR20","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41375-020-0950-6","volume":"35","author":"K Hosokawa","year":"2021","unstructured":"Hosokawa K et al (2021) High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag. Leukemia 35(3):906\u2013909","journal-title":"Leukemia"},{"issue":"7","key":"7057_CR21","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41409-019-0452-1","volume":"54","author":"LP Zhao","year":"2019","unstructured":"Zhao LP et al (2019) Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia. Bone Marrow Transpl 54(7):1161\u20131163","journal-title":"Bone Marrow Transpl"},{"key":"7057_CR22","doi-asserted-by":"crossref","unstructured":"Yamazaki H et al (2022) P827: Efficacy and safety of romiplostim added to immunosuppressive therapy as a first-line treatment in patients with aplastic anemia: a phase 2\/3 clinical trial. HemaSphere 6","DOI":"10.1097\/01.HS9.0000846192.06541.42"},{"issue":"5","key":"7057_CR23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12185-024-03853-6","volume":"120","author":"Y Tezuka","year":"2024","unstructured":"Tezuka Y et al (2024) Expansion effect of romiplostim on hematopoietic stem and progenitor cells versus thrombopoietin and eltrombopag. Int J Hematol 120(5):575\u2013586","journal-title":"Int J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07057-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07057-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07057-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:02:33Z","timestamp":1783976553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07057-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["7057"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07057-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a narrative review of published literature and does not involve any new human participants or animal experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"307"}}